Tuesday, 10 May 2016

Intravenous (IV) Ibuprofen: A Top Priority Painkiller for Patients

Intravenous (IV) ibuprofen market in a transformation stage with changes in medical culture and implementation of new strategies for pain relief.

A non-steroidal anti-inflammatory drug (NSAID), ibuprofen, is used to reduce and management of post-operative and acute pain. The intravenous route of administration for ibuprofen is the most effective of all the other routes. Furthermore, it also helps in reducing fever, inflammation, and trauma. Approval of IV ibuprofen for pediatric use by FDA marked as a significant event for growth in the global market. Rising incidences of cancer, headache, pain, back pain, arthritis, and others are also responsible for growth of the market. The side effects of opioid analgesics, such as allergic reactions, respiratory depression, gastrointestinal events, and sedation are causing an increase in demand of IV ibuprofen.

The Current Scenario:

A survey conducted by STAT-Harvard states that one out of three Americans blame doctors for opioid epidemic overdose in United States. Dr. Sushrut Jangi believes that doctors are not in position to defend themselves when death toll due to overdose rose to 1,173 in 2014 and 1,104 in first nine months of 2015 in Massachusetts. He added that medical community needs to endeavor to get rid of the habit of overprescribing opioids. The origin of epidemics was not due to bad-intentioned doctors as they are rare. Over past two decades, well-intentioned doctors have caught in a web of variety of interests from educational campaigns and pharmaceutical industry. For instance, the introduction of powerful narcotic Oxycontin in mid 90s influenced doctors through educational campaigns by asserting that doctors were undermining pain.

How opioids prescriptions ascended:

Numerous reports suggest that opioids could be useful for treatment of pain without causing addiction. The documentation of pain levels, from 1 to 10, became the topmost priority as per new pain management quality standards that were implemented in 2001. As patient satisfaction surveys increased from that time, hospitals encouraged prescribers to treat pain of patients appropriately to maximize reimbursement. At the same time, US Food and Drug Administration (FDA) was unable to confine increasing use prescriptions by leveraging the existing law. Consequently, opioids prescriptions ascended since 1990s and death toll rose with overdose. Most of the times, patients who died due to opioid addiction, acquired these medicines from either prescription of doctors or recommendations from friends & family.

Why Doctors have no other option:

Doctors have fueled the use of opioid epidemic with their diligent efforts to relieve pain. As a result, these drugs have piled up in American homes. Dr. Jangi emphasized that there has to be a drastic change in medical culture to change this scenario. Opioids have become a priority for relieving pain and treatment for problems, such as kidney stones, gallstone attacks, an ankle sprain, and others. Sometimes, doctors have no option than prescribing dozens of painkillers at the time of discharge as it relieves unbearable pain and acute sufferings after surgeries.

What should be done:

He stated that the tradition of few uncertain decades is responsible for current practice for over prescription. Evidence suggests that temporary bursts on first exposure can cause chronic addiction. According to a study, one third of patients who used opioids after spine surgery continue its use for the next one year. They fail to understand that there are numeral risks and side effects associated and less benefits in treating pain. Hospital should take preventive measures and devise new strategies to reduce opioids prescriptions.

A report published on the Intravenous (IV) ibuprofen market states that the market would reach $14.2 million by 2022 and expected to register a CAGR of 20% from 2016 to 2022. Analysts studying the industry have revealed an exhaustive analysis of current market status, SWOT analysis of key manufacturers, detailed segmentation, and competitive intelligence.